7Baggers

Aclaris Therapeutics, Inc
(NASDAQ:ACRS) 

ACRS stock logo

Aclaris Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drug candidates for immuno-inflammatory diseases in the United States. The Company operates in two segments, Therapeutics and Contract Research. Its products pipeline includes ATI-450, an investigational or...

Founded: 2012
Full Time Employees: 75
Sector: Healthcare
Industry: Biotechnology
Pharmaceuticals
Share this website to your friends
• Market Cap:
• Exchange:
• Shs Outstanding:
• Employees:
• Beta:
• Return on Equity (ROE) ttm:
• Return on Assets (ROA) ttm:
• EPS ttm:
• Book value per Share:
• Cash per Share:
• Current ast per Share:
• P/E ttm:
• P/E forward:
• P/E ttm high:
• P/E ttm low:
• P/S ttm:
• P/B ttm:
• P/FCF ttm:
• PEG ratio:
• Cash Ratio ttm:
• Quick Ratio ttm:
• Current Ratio ttm:
• Gross Mgn ttm:
• EBITDA Mgn ttm:
• Operating Mgn ttm:
• Net Income Mgn ttm:
• Trailing Div yield:
• Forward Div yield:
• Payout Ratio ttm:
• Ex-Dividend date:
• Target Price High:
• Target Price Low:
• Target Price Mean:
• Number of Analysts:
• Debt Ratio ttm:
• Debt to Equity ttm:
• Total Net Debt:
At a glance:
Bull Thesis:
Bear Thesis:
Main Competitors:
Moat:
Income Statements:
Quarterly
Annual
    Unit: USD2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 
                                               
      revenues:
    		                                           
      contract research
    		537,000 500,000 485,000 442,000 445,000 615,000 645,000 625,000 657,000 566,000 705,000 875,000 889,000 866,000 1,090,000 1,218,000 1,221,000 1,274,000 1,415,000 1,606,000 1,535,000 1,413,000 1,331,000 1,853,000 1,189,000 1,095,000 983,000 886,000 1,263,000 1,272,000 1,118,000 1,143,000            
      licensing
    		1,459,000 795,000 2,814,000 1,335,000 1,010,000 8,596,000 3,701,000 2,141,000 1,741,000 17,004,000 8,577,000 994,000 1,639,000 6,722,000 17,898,000                             
      total revenue
    		1,996,000 1,295,000 3,299,000 1,777,000 1,455,000 9,211,000 4,346,000 2,766,000 2,398,000 17,570,000 9,282,000 1,869,000 2,528,000 7,753,000 19,018,000 1,528,000 1,453,000 1,501,000 1,659,000 1,824,000 1,777,000 1,580,000 1,449,000 2,046,000 1,407,000 1,095,000 983,000 5,865,000 5,041,000 3,669,000 1,628,000 3,676,000            
      yoy
    		37.18% -85.94% -24.09% -35.76% -39.32% -47.58% -53.18% 47.99% -5.14% 126.62% -51.19% 22.32% 73.98% 416.52% 1046.35% -16.23% -18.23% -5.00% 14.49% -10.85% 26.30% 44.29% 47.41% -65.12% -72.09% -70.16% -39.62% 59.55%                
      qoq
    		54.13% -60.75% 85.65% 22.13% -84.20% 111.94% 57.12% 15.35% -86.35% 89.29% 396.63% -26.07% -67.39% -59.23% 1144.63% 5.16% -3.20% -9.52% -9.05% 2.64% 12.47% 9.04% -29.18% 45.42% 28.49% 11.39% -83.24% 16.35% 37.39% 125.37% -55.71%             
      costs and expenses:
    		                                           
      cost of revenue
    		395,000 532,000 538,000 515,000 506,000 705,000 654,000 624,000 809,000 725,000 848,000 1,042,000 808,000 877,000 923,000 1,068,000 1,155,000 1,149,000 1,099,000 1,263,000 1,202,000 1,286,000 1,189,000 1,389,000 1,269,000 1,027,000 826,000 2,703,000 2,777,000 3,509,000 1,193,000 1,181,000 967,000 754,000 453,000         
      research and development
    		15,657,000 16,584,000 13,028,000 11,449,000 11,584,000 9,026,000 5,956,000 8,759,000 9,845,000 26,646,000 23,876,000 25,275,000 22,587,000 21,072,000 23,656,000 18,779,000 14,306,000 14,102,000 13,976,000 7,897,000 7,838,000 8,956,000 6,866,000 6,466,000 9,444,000 11,565,000 16,183,000 17,622,000 19,919,000 19,537,000 15,931,000 13,984,000 13,606,000 13,189,000 10,864,000 7,965,000 7,772,000 6,943,000 7,162,000 9,836,000 9,535,000 2,402,000 9,408,000 
      general and administrative
    		6,743,000 5,576,000 4,871,000 5,386,000 6,139,000 4,954,000 5,653,000 4,752,000 6,844,000 8,214,000 7,091,000 8,317,000 8,790,000 7,146,000 5,813,000 6,075,000 6,099,000 6,943,000 5,979,000 5,870,000 4,827,000 4,898,000 3,859,000 5,572,000 6,200,000 6,014,000 6,726,000 7,990,000 8,193,000 6,694,000 6,574,000 8,121,000 6,260,000 12,498,000 8,123,000 7,330,000 5,158,000 4,684,000 3,650,000 3,153,000 3,604,000 2,400,000 1,232,000 
      revaluation of contingent consideration
    		 400,000 100,000 1,500,000 300,000 -1,300,000 800,000 200,000 2,800,000 -26,300,000 1,700,000 -1,500,000 -800,000 7,100,000 2,200,000 -3,400,000 -1,200,000 2,200,000 900,000 4,800,000 16,439,000                       
      total costs and expenses
    		24,188,000 24,029,000 20,448,000 20,185,000 19,539,000 108,886,000 14,817,000 15,620,000 21,329,000 21,617,000 40,859,000 33,684,000 32,446,000 36,832,000 39,892,000 22,522,000 20,360,000 24,394,000 21,954,000 19,830,000 30,306,000 15,140,000 11,914,000 13,427,000 16,913,000 18,648,000 23,847,000 55,656,000 42,376,000               
      income from operations
    		-22,192,000 -22,734,000 -17,149,000 -18,408,000 -18,084,000 -99,675,000 -10,471,000 -12,854,000 -18,931,000 -4,047,000 -31,577,000 -31,815,000 -29,918,000 -29,079,000 -20,874,000 -20,994,000 -18,907,000 -22,893,000 -20,295,000 -18,006,000 -28,529,000 -13,560,000 -10,465,000 -11,381,000 -15,506,000 -17,553,000 -22,864,000 -49,791,000 -37,335,000 -39,038,000 -33,450,000 -31,978,000 -30,948,000 -25,442,000 -18,756,000 -15,295,000 -12,930,000 -11,627,000 -10,812,000 -12,989,000 -13,139,000   
      yoy
    		22.72% -77.19% 63.78% 43.21% -4.47% 2362.94% -66.84% -59.60% -36.72% -86.08% 51.27% 51.54% 58.24% 27.02% 2.85% 16.59% -33.73% 68.83% 93.93% 58.21% 83.99% -22.75% -54.23% -77.14% -58.47% -55.04% -31.65% 55.70% 20.64% 53.44% 78.34% 109.07% 139.35% 118.82% 73.47% 17.75% -1.59%       
      qoq
    		-2.38% 32.57% -6.84% 1.79% -81.86% 851.91% -18.54% -32.10% 367.78% -87.18% -0.75% 6.34% 2.89% 39.31% -0.57% 11.04% -17.41% 12.80% 12.71% -36.89% 110.39% 29.57% -8.05% -26.60% -11.66% -23.23% -54.08% 33.36% -4.36% 16.71% 4.60% 3.33% 21.64% 35.65% 22.63% 18.29% 11.21% 7.54% -16.76% -1.14%    
      operating margin %
    		-1111.82% -1755.52% -519.82% -1035.90% -1242.89% -1082.13% -240.93% -464.71% -789.45% -23.03% -340.20% -1702.25% -1183.47% -375.07% -109.76% -1373.95% -1301.24% -1525.18% -1223.33% -987.17% -1605.46% -858.23% -722.22% -556.26% -1102.06% -1603.01% -2325.94% -848.95% -740.63% -1064.00% -2054.67% -869.91% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% NaN% NaN% 
      other income:
    		                                           
      interest income
    		1,514,000 1,634,000 1,819,000 2,018,000 2,166,000 2,103,000 1,991,000                                   88,000 7,000 
      non-cash royalty income
    		854,000 1,305,000 716,000 961,000 833,000 1,020,000 894,000                                     
      total other income
    		2,368,000 2,939,000 2,535,000 2,979,000 2,999,000 3,123,000 2,885,000                                     
      net income
    		-19,824,000 -19,795,000 -14,614,000 -15,429,000 -15,085,000 -96,552,000 -7,586,000 -10,986,000 -16,941,000 -1,491,000 -29,261,000 -29,569,000 -28,160,000 -27,635,000 -19,952,000 -20,532,000 -18,789,000 -22,804,000 -21,146,000 -18,161,000 -28,754,000 -13,173,000 -10,659,000 -11,597,000 -15,586,000 -18,594,000 -55,319,000 -49,876,000 -37,565,000 -38,551,000 -32,740,000 -31,218,000 -30,229,000 -22,934,000 -18,192,000 -14,838,000 -12,559,000 -11,475,000 -10,694,000 -12,871,000 -13,039,000   
      yoy
    		31.42% -79.50% 92.64% 40.44% -10.96% 6375.65% -74.07% -62.85% -39.84% -94.60% 46.66% 44.01% 49.87% 21.18% -5.65% 13.06% -34.66% 73.11% 98.39% 56.60% 84.49% -29.15% -80.73% -76.75% -58.51% -51.77% 68.96% 59.77% 24.27% 68.10% 79.97% 110.39% 140.70% 99.86% 70.11% 15.28% -3.68%       
      qoq
    		0.15% 35.45% -5.28% 2.28% -84.38% 1172.77% -30.95% -35.15% 1036.22% -94.90% -1.04% 5.00% 1.90% 38.51% -2.82% 9.28% -17.61% 7.84% 16.44% -36.84% 118.28% 23.59% -8.09% -25.59% -16.18% -66.39% 10.91% 32.77% -2.56% 17.75% 4.88% 3.27% 31.81% 26.07% 22.60% 18.15% 9.45% 7.30% -16.91% -1.29%    
      net income margin %
    		-993.19% -1528.57% -442.98% -868.26% -1036.77% -1048.22% -174.55% -397.18% -706.46% -8.49% -315.24% -1582.08% -1113.92% -356.44% -104.91% -1343.72% -1293.12% -1519.25% -1274.62% -995.67% -1618.12% -833.73% -735.61% -566.81% -1107.75% -1698.08% -5627.57% -850.40% -745.19% -1050.72% -2011.06% -849.24% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% NaN% NaN% 
      net income per share
    		-0.15 -0.16 -0.12 -0.13 -0.12 -1.21 -0.11 -0.15 -0.24 -0.02 -0.41 -0.42 -0.42 -0.41 -0.3 -0.31 -0.31 -0.37 -0.35 -0.34 -0.57 -0.3 -0.25 -0.28 -0.37 -0.44 -1.34 -1.21 -0.91 -0.99 -1.06 -1.01 -0.98 -0.76 -0.63 -0.56 -0.48 -0.49 -0.5 -0.62 -0.65 4.65 -5.11 
      weighted-average common shares outstanding, basic and diluted
    		128,810,050 122,564,741 122,619,311 122,580,967 122,390,303 77,296,665 71,381,731 71,291,400 71,074,858 69,808,855 70,807,934 70,633,528 66,872,778 65,213,944 66,675,337 65,990,031 61,431,026 56,730,583 61,219,321 53,968,405 50,337,807 42,539,293 42,802,582 42,133,646 41,618,429 41,323,921 41,364,387 41,274,808 41,248,663 32,909,762 30,982,192 30,944,899 30,885,928 28,102,386 28,834,808 26,594,854 26,080,806 21,415,733 21,415,871 20,663,088 20,171,518 6,107,042 2,274,617 
      other comprehensive income:
    		                                           
      unrealized gain on marketable securities, net of tax of 0
    		-588 13 115 48 337 -330 890  -258    543 -310.25 -139 -354  -224 5 25 -35 -1 -24 -37 60 -13 -23 30 34 34 65 111  -128 63  -52 36 -12 14 142 -155 1 
      total other comprehensive income
    		-588 13 115 48 337        543 -310.25 -139   -221 181 -44 -46 -49 -60 -32 113 -65  57 20 47 72 139 -82 -133 53 83 20 23.75 -55  152 -150 1 
      comprehensive loss
    		-20,412 -19,782 -14,499 -15,381 -14,748 -96,882 -6,696 -11,085 -17,199 -468 -29,279 -30,326 -27,617 -27,067 -20,091 -20,886 -19,537 -23,025 -20,965 -18,205 -28,800 -13,222 -10,719 -11,629 -15,473 -18,659 -55,328 -49,819 -37,545 -38,504 -32,668 -31,079 -30,311 -23,067 -18,139 -14,755 -12,539 -9,127.25 -10,749 -12,873 -12,887 -4,864 -10,632 
      other comprehensive loss:
    		                                           
      total other comprehensive gain
    		     133.25 890  -258                                   
      other income
    		       1,868,000 1,990,000 2,189,000 2,316,000 2,246,000 1,758,000 1,444,000 922,000 462,000 118,000    -225,000   -189,000 178,000 -1,895,000 -274,000 -85,000 -230,000 487,000 710,000 760,000 719,000 678,000 564,000 457,000 371,000 152,000 118,000 118,000 100,000   
      unrealized loss on marketable securities, net of tax of 0
    		       -99  -58 -18 -757     -748                -65           
      total other comprehensive loss
    		       -99  -58 -18 -757    -354 -748                           
      other
    		             165,000 30,000                             
      foreign currency translation adjustment
    		                 3 176 -69 -11                       
      other revenue
    		               310,000 232,000 227,000 244,000 218,000 242,000 167,000 118,000 193,000 218,000     500,000  1,000,000            
      other expense
    		                 89,000 -851,000 -155,000  -51,250 -194,000                     
      loss from continuing operations
    		                 -22,804,000 -21,146,000 -18,161,000 -28,754,000 -13,597,000 -10,659,000 -11,570,000 -15,328,000 -19,448,000 -23,138,000                 
      loss from discontinued operations
    		                     -71,250  -27,000 -258,000 854,000 -32,181,000                 
      goodwill impairment
    		                           18,504,000                
      foreign currency translation adjustments
    		                     5.5 -36 5 53 -52 14 27 -14 13 7 28 -17 -5 -10 87 72 -12.25 -43 -16 10   
      product sales
    		                           4,979,000 3,778,000               
      sales and marketing
    		                         42,000 112,000 7,177,000 9,828,000 12,967,000 11,380,000 12,368,000 11,233,000           
      amortization of definite-lived intangible
    		                           1,660,000 1,659,000               
      eskata product sales
    		                             510,750 510,000 1,533,000            
      gross profit
    		                             160,000 435,000 2,495,000 151,000 245,000 231,000         
      yoy
    		                             -34.69% 88.31%             
      qoq
    		                             -63.22% -82.57% 1552.32% -38.37% 6.06%          
      gross margin %
    		0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 4.36% 26.72% 67.87% Infinity% Infinity% Infinity% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% 
      operating expenses:
    		                                           
      total operating expenses
    		                             39,198,000 33,885,000 34,473,000 31,099,000 25,687,000 18,987,000 15,295,000 12,930,000 11,627,000 10,812,000 12,989,000 13,139,000 4,802,000 10,640,000 
      revenue
    		                                1,118,000 999,000 684,000         
      accretion of convertible preferred stock
    		                                           
      net loss attributable to common stockholders
    		                                     -11,475,000 -10,694,000 -12,871,000 -13,039,000 -4,927,000 -11,628,000 
    Balance Sheets:
    Quarterly
    Annual
      Unit: USD2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 
                                                 
        assets
      		                                           
        current assets:
      		                                           
        cash and cash equivalents
      		28,660,000 19,960,000 25,256,000 25,402,000 30,357,000 24,570,000 47,651,000 22,834,000 35,841,000 39,878,000 39,040,000 31,150,000 44,722,000 45,277,000 61,653,000 68,264,000 36,342,000 27,349,000 53,602,000 113,447,000 35,267,000 22,063,000 23,643,000 32,587,000   29,898,000 31,654,000 34,197,000 57,019,000 26,590,000 46,035,000 54,881,000 20,202,000 60,055,000 32,708,000 23,677,000 30,171,000 17,796,000 31,815,000 13,131,000 9,851,000 25,419,000 
        short-term marketable securities
      		76,756,000 70,791,000 70,656,000 74,404,000 74,957,000 89,024,000 80,071,000 88,259,000 92,325,000 79,228,000 64,012,000 88,625,000 126,081,000 172,294,000 186,409,000 180,339,000 143,280,000 164,065,000 144,280,000 118,227,000 93,028,000                       
        accounts receivable, prepaid expenses and other current assets
      		4,814,000 5,565,000 4,680,000                                         
        total current assets
      		110,230,000 96,316,000 100,592,000 104,202,000 108,790,000 125,951,000 132,330,000 117,635,000 135,338,000 128,856,000 123,068,000 132,935,000 184,361,000 231,550,000 256,573,000 259,354,000 190,881,000 205,032,000 205,782,000 241,261,000 134,501,000 57,493,000 57,997,000 70,955,000 82,714,000 83,803,000 145,370,000 137,894,000 156,813,000 179,499,000 145,519,000 171,172,000 192,256,000 200,221,000 234,122,000 175,751,000 157,349,000 138,556,000 85,590,000 95,638,000 86,833,000 86,524,000 39,360,000 
        marketable securities
      		85,372,000 60,612,000 71,297,000 81,084,000 85,211,000 90,302,000 45,714,000 38,778,000 33,199,000 62,771,000 83,944,000 90,992,000 33,602,000 12,242,000  7,221,000 23,955,000 34,242,000 45,735,000 34,503,000 14,362,000 32,068,000 29,834,000 35,528,000 25,013,000 39,078,000 61,530,000 83,863,000 102,558,000 110,953,000 107,681,000 118,569,000 132,096,000 173,655,000 167,793,000 137,789,000 129,741,000 107,051,000 66,246,000 62,195,000 72,115,000 75,017,000 12,986,000 
        property and equipment
      		750,000 761,000 811,000 868,000 942,000 1,008,000 1,133,000 1,293,000 1,531,000 1,620,000 1,764,000 1,899,000 1,513,000 1,099,000 1,145,000 1,276,000 1,277,000 1,335,000 1,170,000 1,287,000 1,424,000 1,654,000 1,920,000 2,230,000 2,187,000 2,470,000 2,854,000 4,241,000 4,026,000 4,280,000 4,409,000 4,375,000 2,191,000 2,159,000 1,203,000 938,000 706,000 481,000 461,000 434,000 417,000 360,000 761,000 
        other assets
      		2,368,000 2,771,000 2,834,000 2,993,000 3,151,000 3,066,000 3,217,000 3,365,000 3,997,000 3,889,000 2,661,000 2,888,000 3,275,000 2,732,000 2,922,000 3,114,000 3,384,000 3,554,000 3,740,000 3,909,000 4,007,000 4,514,000 4,843,000 4,653,000 4,731,000 4,825,000 4,975,000 5,323,000 2,381,000 332,000 452,000 457,000 341,000 279,000 195,000 20,000 20,000 20,000 20,000 20,000 20,000 22,000 23,000 
        total assets
      		198,720,000 160,460,000 175,534,000 189,147,000 198,094,000 220,327,000 182,394,000 161,071,000 174,065,000 197,405,000 218,354,000 235,649,000 229,705,000 254,596,000 267,632,000 277,976,000 226,527,000 251,211,000 263,494,000 288,046,000 161,399,000 70,784,000 71,902,000 84,999,000 96,812,000 98,297,000 160,416,000 217,239,000 253,183,000 275,566,000 176,176,000 201,819,000 220,622,000 243,509,000 261,391,000 176,808,000 166,210,000 176,085,000 86,071,000 96,092,000 87,270,000 94,076,000 42,087,000 
        liabilities and stockholders’ equity
      		                                           
        current liabilities:
      		                                           
        accounts payable
      		14,731,000 13,158,000 9,187,000 8,797,000 6,354,000 4,690,000 7,662,000 7,269,000 10,810,000 8,878,000 9,648,000 11,425,000 8,190,000 10,351,000 7,667,000 5,703,000 8,121,000 9,985,000 7,564,000 4,244,000 7,292,000 5,254,000 5,081,000 5,502,000 6,946,000 9,917,000 17,780,000 14,160,000 14,574,000 14,755,000 13,735,000 12,504,000 8,155,000 7,822,000 6,483,000 5,848,000 3,604,000 2,845,000 1,774,000 3,309,000 2,808,000 810,000 958,000 
        accrued expenses
      		5,896,000 8,791,000 9,784,000 11,411,000 8,572,000 20,333,000 4,722,000 5,762,000 6,565,000 19,446,000 15,160,000 8,744,000 7,263,000 8,701,000 9,154,000 7,571,000 5,687,000 10,051,000 7,408,000 6,931,000 3,599,000 5,906,000 3,816,000 9,344,000 10,374,000 7,721,000 6,066,000 27,597,000 20,786,000 12,587,000 8,545,000 7,565,000 5,668,000 4,940,000 3,510,000 2,521,000 2,033,000 3,378,000 2,817,000 2,198,000 921,000 745,000 939,000 
        deferred income
      		3,972,000 3,943,000 3,925,000 3,914,000 3,888,000 3,890,000 3,765,000                                     
        other current liabilities
      		2,771,000 2,753,000 2,735,000 2,717,000 2,700,000 2,683,000 2,667,000 2,651,000 2,705,000                                   
        total current liabilities
      		27,370,000 28,645,000 25,631,000 26,839,000 21,514,000 31,596,000 18,816,000 15,682,000 20,080,000 30,952,000 27,320,000 22,829,000 18,258,000 21,938,000 19,789,000 16,217,000 16,726,000 22,931,000 17,839,000 14,916,000 14,505,000 14,874,000 12,788,000 17,745,000 20,603,000 22,432,000 38,989,000 42,748,000 36,228,000 27,342,000 22,280,000 20,069,000 13,823,000 12,762,000 9,993,000 8,369,000 5,637,000 6,223,000 4,591,000 5,507,000 3,729,000 1,555,000 1,897,000 
        other liabilities
      		1,416,000 1,565,000 1,711,000 1,851,000 4,308,000 4,439,000 2,245,000 2,367,000 2,971,000 3,074,000 1,834,000 1,903,000 1,970,000 1,570,000 1,638,000 1,840,000 2,035,000 2,172,000 2,507,000 2,917,000 3,041,000 3,179,000 3,134,000 3,331,000 3,477,000 3,736,000 4,005,000 5,120,000 3,301,000 1,703,000 1,775,000 1,754,000 534,000 558,000 375,000 295,000 284,000 372,000 358,000 345,000 330,000   
        deferred income, net of current portion
      		15,285,000 16,168,000 17,492,000 18,218,000 19,206,000 20,038,000 21,182,000                                     
        contingent consideration
      		11,000,000 11,000,000 10,600,000 10,500,000 9,000,000 8,700,000 10,000,000 9,200,000 9,000,000 6,200,000 32,500,000 30,800,000 32,300,000 33,100,000 26,000,000 23,800,000 27,200,000 28,400,000 26,200,000 25,300,000 20,500,000 4,061,000 4,061,000 3,435,000 3,435,000 1,668,000 1,668,000 1,668,000 934,000 934,000 5,244,000 5,244,000 5,244,000 4,378,000 4,378,000         
        total liabilities
      		55,071,000 57,378,000 55,434,000 57,408,000 54,028,000 64,773,000 52,243,000 27,249,000 32,051,000 40,226,000 62,021,000 55,899,000 52,895,000 56,975,000 47,794,000 42,224,000 46,328,000 53,870,000 46,913,000 54,231,000 49,105,000 33,134,000 31,145,000 35,633,000 38,637,000 28,385,000 75,141,000 80,009,000 70,930,000 60,442,000 29,848,000 27,616,000 20,150,000 18,247,000 17,132,000 8,664,000 5,921,000 6,595,000 4,949,000 5,852,000 4,059,000 1,555,000 1,900,000 
        stockholders’ equity:
      		                                           
        preferred stock, 0.00001 par value...
      		                                           
        common stock, 0.00001 par value...
      		1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000                        
        additional paid‑in capital
      		1,131,234,000 1,070,255,000 1,067,491,000 1,064,631,000 1,061,577,000 1,058,317,000 936,032,000 933,007,000 930,114,000 928,080,000 926,766,000 920,904,000 887,638,000 880,832,000 875,982,000 871,805,000 795,366,000 792,971,000 789,186,000 785,455,000 645,730,000 542,286,000 532,170,000 530,061,000 527,241,000 523,505,000 520,209,000 516,836,000 512,040,000 507,366,000 400,066,000 395,273,000 390,464,000 384,943,000 380,873,000  264,009,000 260,671,000 160,613,000 158,982,000 139,080,000 135,503,000  
        accumulated other comprehensive income
      		22,000 610,000 597,000 482,000 434,000 97,000 427,000                 15,000 47,000               1,000 3,000  1,000 
        accumulated deficit
      		-987,608,000 -967,784,000 -947,989,000 -933,375,000 -917,946,000 -902,861,000 -806,309,000 -798,723,000 -787,737,000 -770,796,000 -769,305,000 -740,044,000 -710,475,000 -682,315,000 -654,680,000 -634,728,000 -614,196,000 -595,407,000 -572,603,000 -551,457,000 -533,296,000 -504,542,000 -491,369,000 -480,710,000 -469,113,000 -453,527,000 -434,933,000 -379,614,000 -329,738,000 -292,173,000 -253,622,000 -220,882,000 -189,664,000 -159,435,000 -136,501,000 -118,309,000 -103,471,000 -90,912,000 -79,437,000 -68,743,000 -55,872,000 -42,833,000  
        total stockholders’ equity
      		143,649,000 103,082,000 120,100,000 131,739,000 144,066,000 155,554,000 130,151,000 133,822,000 142,014,000 157,179,000 156,333,000 179,750,000 176,810,000 197,621,000 219,838,000 235,752,000 180,199,000 197,341,000 216,581,000 233,815,000 112,294,000 37,650,000 40,757,000 49,366,000 58,175,000 69,912,000 85,275,000 137,230,000 182,253,000 215,124,000 146,328,000 174,203,000 200,472,000 225,262,000 244,259,000 168,144,000 160,289,000 169,490,000 81,122,000 90,240,000 83,211,000 92,521,000  
        total liabilities and stockholders’ equity
      		198,720,000 160,460,000 175,534,000 189,147,000 198,094,000 220,327,000 182,394,000 161,071,000 174,065,000 197,405,000 218,354,000 235,649,000 229,705,000 254,596,000 267,632,000 277,976,000 226,527,000 251,211,000 263,494,000 288,046,000 161,399,000 70,784,000 71,902,000 84,999,000 96,812,000 98,297,000 160,416,000 217,239,000 253,183,000 275,566,000 176,176,000 201,819,000 220,622,000 243,509,000 261,391,000 176,808,000 166,210,000 176,085,000 86,071,000 96,092,000 87,270,000   
        accounts receivable
      		   194,000 250,000 318,000 343,000 325,000 373,000 298,000 346,000 431,000 686,000 484,000 597,000 637,000 633,000 623,000 811,000 939,000 817,000 772,000 887,000 775,000 933,000 704,000 673,000 19,370,000 15,817,000 4,861,000 1,033,000 2,182,000 529,000 481,000 658,000         
        prepaid expenses and other current assets
      		   4,202,000 3,226,000 12,039,000 4,265,000 6,217,000 6,799,000 9,452,000 19,670,000 12,729,000 12,872,000 13,495,000 7,914,000 10,114,000 10,626,000 12,995,000 7,089,000 8,648,000 5,389,000 2,590,000 1,880,000 2,065,000 2,776,000 3,118,000 2,089,000 2,822,000 3,385,000 5,875,000 9,171,000 3,360,000 4,750,000 5,883,000 5,616,000 5,254,000 3,931,000 1,334,000 1,548,000 1,628,000 1,587,000 1,656,000 955,000 
        accumulated other comprehensive loss
      		       -463,000 -364,000 -106,000 -1,129,000 -1,111,000 -354,000 -897,000 -1,465,000 -1,326,000 -972,000 -224,000 -3,000 -184,000 -140,000 -94,000 -44,000   -66,000  8,000 -49,000 -69,000 -116,000 -188,000 -328,000 -246,000 -113,000 -166,000 -249,000 -269,000 -54,000   -149,000  
        intangible assets
      		         269,000 6,917,000 6,935,000 6,954,000 6,973,000 6,992,000 7,011,000 7,030,000 7,048,000 7,067,000 7,086,000 7,105,000 7,123,000 7,142,000 7,161,000 7,180,000 7,199,000 7,217,000 69,781,000 71,459,000 72,951,000 7,292,000 7,311,000 7,330,000 7,349,000 7,367,000         
        current portion of lease liabilities
      		         426,000 310,000 458,000 603,000 684,000 766,000 741,000 716,000 693,000 669,000 647,000 625,000 603,000 591,000 610,000 624,000 637,000 642,000 991,000 868,000               
        discontinued operations
      		         2,202,000 2,202,000 2,202,000 2,202,000 2,202,000 2,202,000 2,202,000 2,202,000                           
        deferred tax liability
      		          367,000 367,000 367,000 367,000 367,000 367,000 367,000 367,000 367,000 367,000 367,000 367,000 549,000 549,000 549,000 549,000 549,000 549,000 549,000 549,000 549,000 549,000 549,000 549,000 2,386,000         
        commitments and contingencies
      		                                           
        discontinued operations - current liabilities
      		                 2,202,000 2,198,000 3,094,000 2,989,000 3,111,000 3,300,000 2,289,000 2,659,000 4,157,000 14,501,000                 
        long-term debt
      		                   10,731,000 10,692,000 10,653,000 10,613,000 10,573,000 10,573,000  29,930,000 29,924,000 29,918,000 29,914,000              
        restricted cash
      		                      1,753,000                     
        discontinued operations - current assets
      		                         4,966,000 51,180,000                 
        cash, cash equivalents and restricted cash
      		                        53,992,000 35,937,000                  
        inventory
      		                           185,000 856,000 791,000 1,044,000 1,026,000            
        goodwill
      		                            18,504,000 18,504,000 18,504,000 18,504,000 18,504,000 18,504,000 18,504,000         
        discontinued operations - non-current assets
      		                                           
        discontinued operations - non-current liabilities
      		                                           
        deferred offering costs
      		                                   99,000 116,000 116,000     1,943,000 
        additional paid-in capital
      		                                   286,619,000        
        liabilities, convertible preferred stock and stockholders’ equity
      		                                           
        deferred rent
      		                                          3,000 
        convertible preferred stock (series a, b and c), 0.00001 par value...
      		                                          78,305,000 
        stockholders’ equity
      		                                           
        total liabilities, convertible preferred stock and stockholders’ equity
      		                                         94,076,000  
        liabilities, convertible preferred stock and stockholders’ deficit
      		                                           
        stockholders’ deficit:
      		                                           
        total stockholders’ deficit
      		                                           
        total liabilities, convertible preferred stock and stockholders’ deficit
      		                                          42,087,000 
      Cashflow Statements:
      Quarterly
      Annual
        Unit: USD2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 
                                                  
          cash flows from operating activities:
        		                                          
          net loss
        		-19,824,000 -19,795,000 -14,614,000 -15,429,000 -15,085,000 -96,552,000 -7,586,000 -10,986,000 -16,941,000 -1,491,000 -29,261,000 -29,569,000 -28,160,000 -27,635,000 -19,952,000 -20,532,000 -18,789,000 -22,804,000 -21,146,000 -18,161,000 -28,754,000 -13,173,000 -10,659,000 -11,597,000 -15,586,000 -18,594,000 -55,319,000 -49,876,000 -37,565,000 -38,551,000 -32,740,000 -31,218,000 -30,229,000 -22,934,000 -18,192,000 -14,838,000 -12,559,000 -11,475,000 -10,694,000 -12,871,000 -13,039,000 -4,714,000 
          adjustments to reconcile net loss to net cash from operating activities:
        		                                          
          depreciation and amortization
        		102,000 102,000 110,000 114,000 128,000 143,000 179,000 242,000 243,000 228,000 219,000 218,000 198,000 190,000 193,000 206,000 208,000 197,000 191,000 247,000 288,000 -449,000 591,000 606,000 576,000 320,000 1,632,000 2,231,000 2,226,000 958,000 384,000 315,000 222,000 181,000         
          stock-based compensation expense
        		3,198,000 2,926,000 2,860,000 3,063,000 3,535,000 2,860,000 3,004,000 2,903,000 2,089,000 1,266,000 5,948,000 6,522,000 6,806,000 4,813,000 4,188,000 3,692,000 2,346,000 3,851,000 3,702,000 3,832,000 2,675,000 2,504,000 1,941,000 3,309,000 3,453,000 3,181,000 3,320,000 4,814,000 4,862,000 4,956,000 4,707,000 5,249,000 5,143,000 4,300,000 3,673,000 3,304,000 3,153,000 1,910,000 1,618,000 1,354,000 1,222,000 648,000 
          revaluation of contingent consideration
        		 400,000 100,000 1,500,000 300,000 -1,300,000 800,000 200,000 2,800,000 -26,300,000 1,700,000 -1,500,000 -800,000 7,100,000 2,200,000 -3,400,000 -1,200,000 2,200,000 900,000 4,800,000 16,439,000                      
          changes in operating assets and liabilities:
        		                                          
          accounts receivable, prepaid expenses and other assets
        		742,000 -672,000                                         
          accounts payable
        		1,513,000 3,963,000 377,000 2,443,000 1,664,000 -2,972,000 393,000 -3,541,000 1,932,000 -394,000 -2,153,000 3,235,000 -2,161,000 2,687,000 1,964,000 -2,418,000 -1,865,000 2,362,000 2,583,000 -3,132,000 1,842,000 229,000 578,000 -1,709,000 -4,317,000 -6,210,000 3,633,000 -386,000 -197,000 1,032,000 1,239,000 4,377,000 316,000 1,434,000 -31,000 2,330,000 831,000 895,000 -1,578,000 485,000 2,008,000  
          accrued expenses and other liabilities
        		-3,026,000 1,251,000 1,295,000 399,000 -11,042,000 11,572,000                                     
          deferred income
        		-854,000 -1,306,000 -715,000 -962,000 -833,000 -1,020,000                                     
          net cash from operating activities
        		-18,149,000 -13,131,000 -10,932,000 -9,993,000 -13,057,000 -8,938,000 22,000,000 -12,322,000 -20,815,000 -6,761,000 -24,557,000 -20,654,000 -26,353,000 -19,115,000 -7,817,000 -19,666,000 -20,969,000 -17,075,000 -10,606,000 -12,221,000 -12,232,000 -8,857,000 -12,150,000 -10,821,000 -6,805,000 -20,390,000 -23,359,000 -21,378,000 -31,318,000 -27,248,000 -29,858,000 -21,833,000 -21,872,000 -18,210,000 -13,714,000 -10,080,000 -12,659,000 -8,072,000 -9,905,000 -9,732,000 -6,894,000  
          capital expenditures
        		47,000 -15,000 -23,000 -21,000 -43,000 0 0 14,000  -441,000 -102,000 -231,000 -512,000 -85,000 -218,000 -225,000 -53,000 -200,000 -56,000 0  -8,000 -304,000 306,000 -108,000 -349,000 -1,007,000 127,000 -260,000 -87,000 -900,000 -120,000 -88,000 -323,000 -440,000 -94,000 -104,000 -64,000 -69,000 -88,000 0  
          free cash flows
        		-18,102,000 -13,146,000 -10,955,000 -10,014,000 -13,100,000 -8,938,000 22,000,000 -12,308,000  -7,202,000 -24,659,000 -20,885,000 -26,865,000 -19,200,000 -8,035,000 -19,891,000 -21,022,000 -17,275,000 -10,662,000 -12,221,000  -8,865,000 -12,454,000 -10,515,000 -6,913,000 -20,739,000 -24,366,000 -21,251,000 -31,578,000 -27,335,000 -30,758,000 -21,953,000 -21,960,000 -18,533,000 -14,154,000 -10,174,000 -12,763,000 -8,136,000 -9,974,000 -9,820,000 -6,894,000  
          cash flows from investing activities:
        		                                          
          purchases of property and equipment
        		-13,000 -24,000 -23,000 -21,000 -43,000 0 0 14,000 -135,000 -441,000 -84,000 -231,000 -553,000 -105,000 -150,000 -186,000 -164,000 -200,000 -56,000   -8,000 -304,000 -17,000 -124,000 -266,000 -822,000 -241,000 -284,000 -146,000 -560,000 -352,000 -298,000 -577,000 -270,000 -193,000 -195,000 -62,000 -64,000 -66,000 -40,000  
          purchases of marketable securities
        		-51,669,000 -4,608,000 -5,198,000 -19,930,000 -9,996,000 -70,427,000 -14,337,000   0 -17,162,000 -89,989,000 -28,524,000 -46,024,000 -33,633,000 -70,538,000 -14,558,000 -35,291,000 -52,573,000 -61,475,000 -85,814,000 -7,816,000 -12,759,000 -18,270,000 -8,869,000 -16,082,000 -31,896,000 -16,307,000 -73,100,000 -49,254,000 -38,098,000 -38,632,000 -35,614,000 -76,841,000 -78,962,000 -24,376,000 -17,158,000 -115,017,000 -22,465,000    
          proceeds from sales and maturities of marketable securities
        		20,750,000 15,001,000 19,051,000 24,998,000 29,991,000 17,514,000 17,132,000 34,530,000 16,968,000 7,991,000 49,780,000 70,558,000 54,875,000 48,831,000 35,000,000 49,501,000 44,654,000 26,315,000 14,957,000 16,057,000 10,500,000 5,519,000 18,300,000 7,800,000 22,935,000 38,600,000 54,391,000 35,500,000 82,000,000 46,016,000 49,052,000 52,270,000 92,105,000 55,853,000 49,022,000 24,343,000 23,309,000 37,261,000 18,402,000 21,216,000 10,214,000 155,000 
          payments of deferred transaction consideration for in-licensed assets
        		                                          
          net cash from investing activities
        		-30,932,000 10,369,000 13,830,000 5,047,000 19,119,000 -88,723,000 2,795,000 -674,000 16,833,000 7,550,000 32,534,000 -19,662,000 25,798,000 2,702,000 1,217,000 -21,223,000 29,932,000 -9,176,000 -37,672,000 -45,470,000 -75,314,000 -2,305,000 5,237,000 -10,487,000 13,942,000 56,438,000 21,673,000 18,952,000 8,616,000 -70,506,000 10,394,000 13,286,000 56,193,000   -226,000 5,956,000 -77,818,000 -4,127,000 9,868,000 10,174,000  
          cash flows from financing activities:
        		                                          
          proceeds from issuance of common stock under the at-the-market sales agreement, net of issuance costs
        		57,880,000         0 0   0 0                   0 0        
          payments of employee withholding taxes related to restricted stock unit award vesting
        		-250,000 -162,000 0 -9,000 -275,000  -10,000 -11,000 -55,000 0    0 -11,000                            
          proceeds from exercise of employee stock options and the issuance of stock
        		151,000     0    49,000 15,000   37,000 0 83,000 37,000 0 0 1,043,000 416,000                      
          net cash from financing activities
        		57,781,000 -2,534,000 -3,044,000 -9,000 -275,000 74,580,000 22,000 -11,000 -55,000 49,000 -87,000   37,000 -11,000 72,811,000 30,000 -2,000 -11,567,000 135,871,000 100,750,000 7,829,000 -278,000 -97,000 10,918,000 -30,009,000 -70,000 -117,000 -120,000 128,183,000 19,000 -299,000 358,000 -78,000 80,918,000 19,337,000 209,000 98,265,000 13,000    
          net increase in cash and cash equivalents
        		8,700,000  -146,000 -4,955,000 5,787,000     838,000 7,890,000 -13,572,000 -555,000 -16,376,000 -6,611,000 31,922,000 8,993,000        18,055,000 6,039,000 -1,756,000 -2,543,000 -22,822,000 30,429,000 -19,445,000 -8,846,000 34,679,000 -39,853,000 27,347,000 9,031,000 -6,494,000 12,375,000 -14,019,000 18,684,000 3,280,000 -15,568,000 
          cash and cash equivalents at beginning of period
        		19,960,000 0 0 0 24,570,000 0 0 0 39,878,000 0 0 0 45,277,000 0 0 0 27,349,000          0 0 57,019,000 0 0 0 20,202,000 0 0 0 30,171,000 0 0 0 9,851,000 0 
          cash and cash equivalents at end of period
        		28,660,000 -5,296,000 -146,000 -4,955,000 30,357,000 -23,081,000 24,817,000 -13,007,000 35,841,000 838,000 7,890,000 -13,572,000 44,722,000 -16,376,000 -6,611,000 31,922,000 36,342,000          -1,756,000 -2,543,000 34,197,000 30,429,000 -19,445,000 -8,846,000 54,881,000 -39,853,000 27,347,000 9,031,000 23,677,000 12,375,000 -14,019,000 18,684,000 13,131,000 -15,568,000 
          supplemental disclosure of non-cash investing activities:
        		                                          
          additions to property and equipment included in accounts payable
        		60,000 9,000         -18,000   20,000 -68,000 -39,000 111,000       323,000 16,000 -83,000 -185,000 368,000 24,000 59,000 -340,000 232,000 210,000 254,000 -170,000 99,000 91,000 -2,000 -5,000 -22,000 40,000  
          in-process research and development expense
        		                                          
          acquisition of in-licensed assets, including transaction costs
        		                                          
          proceeds from issuance of common stock under securities purchase agreement, net of issuance costs
        		                                          
          net decrease in cash and cash equivalents
        		       -13,007,000 -4,037,000                                  
          supplemental disclosure of non-cash investing and financing activities:
        		                                          
          fair value of warrants issued in connection with in-license agreement
        		                                          
          deferred transaction consideration in connection with in-license agreement
        		                                          
          payment of deferred transaction consideration for in-licensed assets
        		  0 0 -833,000                                      
          accounts receivable
        		   56,000 68,000 25,000 -18,000 48,000 -75,000 48,000 85,000 255,000 -202,000 113,000 40,000 -4,000 -10,000 188,000 128,000 -122,000 -45,000 115,000 -112,000 158,000 4,737,000 12,194,000 1,506,000 -3,553,000 -10,956,000 -3,828,000 1,149,000            
          prepaid expenses and other assets
        		   -1,177,000 8,208,000 -8,599,000 1,427,000 273,000 2,044,000 7,978,000 -7,688,000 -731,000 -874,000 -5,702,000 2,099,000 1,121,000 188,000 -5,609,000 5,215,000 -2,973,000 -2,250,000 386,000 413,000 552,000 338,000 -650,000 1,305,000 119,000 1,854,000 3,421,000 -5,806,000 1,323,000 1,022,000 25,000 -434,000 -1,300,000 -2,597,000  80,000 -41,000 71,000  
          deferred taxes
        		                                          
          payments of employee withholding taxes related to restricted stock unit award vesting and exercise of employee stock options
        		                                          
          accrued expenses
        		       -1,461,000 -12,907,000 5,642,000 6,593,000 916,000 -1,160,000 -681,000 1,451,000 1,669,000 -1,847,000 2,540,000 -2,931,000 3,288,000 -2,427,000 1,713,000 -5,528,000 -2,140,000 2,227,000 -8,784,000 -7,070,000 5,364,000 8,523,000 3,929,000 1,227,000 848,000 788,000 621,000 1,154,000 369,000 -1,537,000 460,000 637,000 1,314,000 39,000 -16,000 
          loss on extinguishment of debt
        		                 0                         
          intangible asset impairment charge
        		                         0                 
          proceeds from issuance of common stock in connection with public offerings, net of issuance costs
        		                 0 0                        
          repayment of debt
        		                 0                         
          restricted stock unit employee tax withholdings
        		                -7,000 -2,000 -84,000 -24,000 -3,014,000                      
          additions to property and equipment included in accrued expenses
        		            41,000                              
          proceeds from issuance of common stock in connection with an equity purchase agreement, net of issuance costs
        		                                          
          proceeds from debt financing (including warrants), net of issuance costs
        		                     0 0 -37,000 10,950,000                  
          finance lease payments
        		                     -9,000 -36,000 -35,000 -57,000 -131,000 -152,000 -120,000 -120,000              
          deferred issuance costs
        		                     31,000                     
          fair value of warrants issued in connection with debt financing
        		                                          
          fair value of common stock issued in connection with an equity purchase agreement
        		                                          
          offering costs included in accounts payable
        		                        30,000     190,000 0 0 20,000 -87,000         
          goodwill impairment charge
        		                         0 0                
          gain on sale of rhofade
        		                                          
          disposition of rhofade
        		                                          
          net increase in cash, cash equivalents and restricted cash
        		                 -26,253,000 -59,845,000 78,180,000 13,204,000                      
          cash, cash equivalents and restricted cash at beginning of period
        		                 0 0 0 22,063,000 0 0 0 35,937,000                  
          cash, cash equivalents and restricted cash at end of period
        		                 -26,253,000 -59,845,000 78,180,000 35,267,000 -3,333,000 -7,191,000 -21,405,000 53,992,000                  
          operating lease asset recorded as a result of new accounting standard
        		                            2,132,000              
          proceeds from issuance of common stock in connection with public offering, net of issuance costs
        		                    103,348,000             0         
          change in fair value of contingent consideration
        		                     0 626,000 0 1,767,000 0 0   406,000 0 0 866,000          
          payment of confluence development milestone
        		                                          
          acquisition of rhofade
        		                                          
          ​
        		                                          
          property and equipment obtained pursuant to finance lease financing arrangements
        		                                          
          fair value of stock issued in connection with confluence development milestone
        		                                          
          net decrease in cash, cash equivalents and restricted cash
        		                                          
          fair value of common stock issued in connection with equity purchase agreement
        		                                          
          proceeds from the issuance of stock
        		                        25,000                  
          inventory
        		                         3,000 -4,000 671,000 -65,000 1,146,000 -18,000            
          acquisition of confluence, net of cash acquired
        		                                 0         
          proceeds from debt financing, net of issuance costs
        		                                          
          proceeds from the exercise of employee stock options
        		                         122,000 82,000   0 183,000 0 394,000 0 0 26,000 209,000 107,000 13,000    
          fair value of stock issued in connection with confluence acquisition
        		                                 0         
          property and equipment obtained pursuant to capital lease financing arrangements
        		                             55,000 180,000            
          write-down of equipment held for sale
        		                                          
          non-cash charge related to vixen acquisition
        		                                          
          proceeds from issuance of common stock in connection with private placement, net of issuance costs
        		                                     0 0    
          capital lease payments
        		                             -149,000 -164,000 -299,000 -36,000          
          fair value of stock issued in settlement of confluence development milestone
        		                                          
          write-down of property and equipment held for sale
        		                                          
          non-cash charges related to vixen acquisition
        		                                     0 0 0 2,784,000  
          proceeds from initial public offering, net of issuance costs
        		                                          
          proceeds from issuance of redeemable convertible preferred stock, net of issuance costs
        		                                          
          fair value of stock issued in connection with vixen acquisition
        		                                     0 0    
          accretion of convertible preferred stock to redemption value
        		                                         0 
          net cash (used in), provided by investing activities
        		                                          
          depreciation expense
        		                                   55,000 50,000 40,000 32,000 27,000 21,000 33,000 
          proceeds from follow-on public offering, net of issuance costs
        		                                          
          fair value of preferred stock purchased put option on date of issuance
        		                                          
          payment of deferred offering costs
        		                                          
          deferred offering costs included in accounts payable
        		                                          
          fair value of stock issued in connection with vixen acquisition on date of issuance
        		                                        2,355,000  
          deferred rent
        		                                          
          proceeds from initial public offering, net of offering costs
        		                                          
          additions to property and equipment purchases included in accounts payable
        		                                         -17,000 
          net cash (used in) provided by investing activities
        		                                          
          proceeds from issuance of convertible preferred stock, net of issuance costs
        		                                          
          payments of initial public offering costs
        		                                          
          net cash provided by financing activities
        		                                          
          deferred offering costs included in accounts payable and accrued expenses